Letter to the Editor From Yang et al: “Prevalence of Postoperatively Detected High-Risk Features in 2- to 4-cm Papillary Thyroid Cancers”Yang, Shijie; Tan, Meijuan; Gao, Feng; Xu, Xiequn
doi: 10.1210/clinem/dgac753pmid: 36592380
Accepted manuscripts Accepted manuscripts are PDF versions of the author’s final manuscript, as accepted for publication by the journal but prior to copyediting or typesetting. They can be cited using the author(s), article title, journal title, year of online publication, and DOI. They will be replaced by the final typeset articles, which may therefore contain changes. The DOI will remain the same throughout. Article PDF first page preview Close PDF This content is only available as a PDF. © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: [email protected] This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
Response to Letter to the Editor From Yang et al: “Prevalence of Postoperatively Detected High-Risk Features in 2- to 4-cm Papillary Thyroid Cancers”Choi, Jee-Hye; Lee, Ja Kyung; Kim, Woochul; Yu, Hyeong Won; Kim, Su-jin; Chai, Young Jun; Choi, June Young; Lee, Kyu Eun
doi: 10.1210/clinem/dgac754pmid: 36611244
Accepted manuscripts Accepted manuscripts are PDF versions of the author’s final manuscript, as accepted for publication by the journal but prior to copyediting or typesetting. They can be cited using the author(s), article title, journal title, year of online publication, and DOI. They will be replaced by the final typeset articles, which may therefore contain changes. The DOI will remain the same throughout. Article PDF first page preview Close PDF This content is only available as a PDF. © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: [email protected] This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
Correction to “Intra-individual Variability of Serum Aldosterone and Implications for Primary Aldosteronism Screening”doi: 10.1210/clinem/dgad012pmid: 36689278
In the above-named article by Maciel AAW, Freitas TC, Fagundes GFC, Petenuci J, Vilela LAP, Brito LP, Goldbaum TS, Zerbini MCN, Ledesma FL, Yanno FY, Srougi V, Chambo JL, Pereira MAA, Coelho FMA, Cavalcante ACBS, Carnevale FC, Pilan B, Pio-Abreu A, Silveira JV, Consolim-Colombo FM, Bortolotto LA, Latronico AC, Fragoso MCBV, Drager LF, Mendonca BB, and Almeida MQ (J Clin Endo Metab. 2022; doi: 10.1210/clinem/dgac679), there was an error in the Funding section: Funders were left out of the Funding section as first published. The Funding section originally read: “This work was supported by São Paulo Research Foundation (FAPESP) grant 2019/15873-6 (to M.Q.A.).” The section should read: “This work was supported by São Paulo Research Foundation (FAPESP) grant 2019/15873-6 (to M.Q.A.), by the FAPESP fellowship 2021/09879-1 (to A.A.W.M.) and by National Council for Scientific and Technological Development (CNPq) 304091/2021-9 (to M.Q.A.)” The article has been corrected online. doi: 10.1210/clinem/dgac679 © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: [email protected] This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
Correction to: “GLP-1 Receptor Agonists and SGLT-2 Inhibitors as Adjuncts to Insulin in Type 1 Diabetes: Benefits and Concerns”doi: 10.1210/clinem/dgad022pmid: 36656760
In the above-named article by Dimitriadis GD, and Lambadiari V (J Clin Endo Metab. 2022; 10.1210/clinem/dgac704), an error occurred in the Data Availability Statement: The Data Availability Statement, “VIANEX is the biggest Greek Pharmaceutical Company and can easily be found in Google” has been removed from the article. The article has been corrected online. https://doi.org/10.1210/clinem/dgac704 © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: [email protected] This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
Correction to: “Aldosterone, Renin, and Aldosterone-to-Renin Ratio Variability in Screening for Primary Aldosteronism”doi: 10.1210/clinem/dgad023pmid: 36656668
In the above-named article by Ng E, Gwini SM, Libianto R, Choy KW, Lu ZX, Shen J, Doery JCG, Fuller PJ, and Yang J (J Clin Endo Metab. 2023; 108(1): 33-41; doi: 10.1210/clinem/dgac568), in Table 1 there were errors in the columns titled “PA (n = 162)” and “Comparison between groups (p-value):” The data in bold below in the columns titled “PA (n = 162)” and “Comparison between groups (p-value)” were missing from the table as first published: Table 1. Patient characteristics Characteristic . PA (n=162) . Comparison between groups (P-value) . Age (years): median (Q1, Q3) 54 (44, 59) 0.005 Sex: n(%) Males 79 (48.8) 0.055 Females 83 (51.2) SBP (mmHg): mean(SD) 148 (18) 0.003 DBP (mmHg): mean(SD) 92 (12) 0.005 SBP > 150 and/or DBP > 100, n(%) 71 (43.8) 0.042 Resistant hypertension#, n(%) 35 (21.6) PAC Intra-individual average* (pmol/L): median(Q1, Q3) 451 (351, 584) <0.001 Number of tests: mean(SD) 3.1 (1.1) 0.047 DRC Intra-individual average* (mU/L): median(Q1, Q3) 3.8 (2.3, 6.1) <0.001 Number of tests: mean(SD) 3.1 (1.1) 0.043 Intra-individual average DRC < 8mU/L, n(%)^ 137 (84.6) <0.001 ARR Intra-individual average* (pmol/L:mU/L): median(Q1, Q3) 133 (83, 237) <0.001 With at least one ARR < 70: n(%) 62 (38.3) <0.001 With first ARR < 70: n(%) 4 (2.5) <0.001 Potassium Intra-individual average* (mmol/L): mean(SD) 4.0 (0.4) 0.002 Range of intra-individual averages (mmol/L) 3.0–4.7 eGFR Intra-individual average* (mL/min): median(Q1, Q3) 90 (84, 90) 0.812 Blood test timing (am): median(Q1, Q3) 9:33 (9:06, 10:11) 0.412 Interval between first & last measurement (days) : median(Q1, Q3) 162 (80, 328) <0.001 Characteristic . PA (n=162) . Comparison between groups (P-value) . Age (years): median (Q1, Q3) 54 (44, 59) 0.005 Sex: n(%) Males 79 (48.8) 0.055 Females 83 (51.2) SBP (mmHg): mean(SD) 148 (18) 0.003 DBP (mmHg): mean(SD) 92 (12) 0.005 SBP > 150 and/or DBP > 100, n(%) 71 (43.8) 0.042 Resistant hypertension#, n(%) 35 (21.6) PAC Intra-individual average* (pmol/L): median(Q1, Q3) 451 (351, 584) <0.001 Number of tests: mean(SD) 3.1 (1.1) 0.047 DRC Intra-individual average* (mU/L): median(Q1, Q3) 3.8 (2.3, 6.1) <0.001 Number of tests: mean(SD) 3.1 (1.1) 0.043 Intra-individual average DRC < 8mU/L, n(%)^ 137 (84.6) <0.001 ARR Intra-individual average* (pmol/L:mU/L): median(Q1, Q3) 133 (83, 237) <0.001 With at least one ARR < 70: n(%) 62 (38.3) <0.001 With first ARR < 70: n(%) 4 (2.5) <0.001 Potassium Intra-individual average* (mmol/L): mean(SD) 4.0 (0.4) 0.002 Range of intra-individual averages (mmol/L) 3.0–4.7 eGFR Intra-individual average* (mL/min): median(Q1, Q3) 90 (84, 90) 0.812 Blood test timing (am): median(Q1, Q3) 9:33 (9:06, 10:11) 0.412 Interval between first & last measurement (days) : median(Q1, Q3) 162 (80, 328) <0.001 Open in new tab Table 1. Patient characteristics Characteristic . PA (n=162) . Comparison between groups (P-value) . Age (years): median (Q1, Q3) 54 (44, 59) 0.005 Sex: n(%) Males 79 (48.8) 0.055 Females 83 (51.2) SBP (mmHg): mean(SD) 148 (18) 0.003 DBP (mmHg): mean(SD) 92 (12) 0.005 SBP > 150 and/or DBP > 100, n(%) 71 (43.8) 0.042 Resistant hypertension#, n(%) 35 (21.6) PAC Intra-individual average* (pmol/L): median(Q1, Q3) 451 (351, 584) <0.001 Number of tests: mean(SD) 3.1 (1.1) 0.047 DRC Intra-individual average* (mU/L): median(Q1, Q3) 3.8 (2.3, 6.1) <0.001 Number of tests: mean(SD) 3.1 (1.1) 0.043 Intra-individual average DRC < 8mU/L, n(%)^ 137 (84.6) <0.001 ARR Intra-individual average* (pmol/L:mU/L): median(Q1, Q3) 133 (83, 237) <0.001 With at least one ARR < 70: n(%) 62 (38.3) <0.001 With first ARR < 70: n(%) 4 (2.5) <0.001 Potassium Intra-individual average* (mmol/L): mean(SD) 4.0 (0.4) 0.002 Range of intra-individual averages (mmol/L) 3.0–4.7 eGFR Intra-individual average* (mL/min): median(Q1, Q3) 90 (84, 90) 0.812 Blood test timing (am): median(Q1, Q3) 9:33 (9:06, 10:11) 0.412 Interval between first & last measurement (days) : median(Q1, Q3) 162 (80, 328) <0.001 Characteristic . PA (n=162) . Comparison between groups (P-value) . Age (years): median (Q1, Q3) 54 (44, 59) 0.005 Sex: n(%) Males 79 (48.8) 0.055 Females 83 (51.2) SBP (mmHg): mean(SD) 148 (18) 0.003 DBP (mmHg): mean(SD) 92 (12) 0.005 SBP > 150 and/or DBP > 100, n(%) 71 (43.8) 0.042 Resistant hypertension#, n(%) 35 (21.6) PAC Intra-individual average* (pmol/L): median(Q1, Q3) 451 (351, 584) <0.001 Number of tests: mean(SD) 3.1 (1.1) 0.047 DRC Intra-individual average* (mU/L): median(Q1, Q3) 3.8 (2.3, 6.1) <0.001 Number of tests: mean(SD) 3.1 (1.1) 0.043 Intra-individual average DRC < 8mU/L, n(%)^ 137 (84.6) <0.001 ARR Intra-individual average* (pmol/L:mU/L): median(Q1, Q3) 133 (83, 237) <0.001 With at least one ARR < 70: n(%) 62 (38.3) <0.001 With first ARR < 70: n(%) 4 (2.5) <0.001 Potassium Intra-individual average* (mmol/L): mean(SD) 4.0 (0.4) 0.002 Range of intra-individual averages (mmol/L) 3.0–4.7 eGFR Intra-individual average* (mL/min): median(Q1, Q3) 90 (84, 90) 0.812 Blood test timing (am): median(Q1, Q3) 9:33 (9:06, 10:11) 0.412 Interval between first & last measurement (days) : median(Q1, Q3) 162 (80, 328) <0.001 Open in new tab The publisher acknowledges the errors. The article has been corrected online. https://doi.org/10.1210/clinem/dgac568 © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: [email protected] This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)